– USA, CA – Agilent Technologies, Inc. (NYSE: A) today announced the election of Dr. Otis Brawley, to its board of directors, effective Nov. 17, 2021.
“We’re very pleased to welcome Otis to the Agilent board. I’m extremely confident we will benefit from his ongoing active leadership in oncology research and the issues that need to be addressed in order to ensure the best possible outcomes for all cancer patients,” said Board Chair, Koh Boon Hwee.
Mike McMullen, president, and CEO added: “It’s a special honor to have someone with Otis’ deep academic and medical expertise join the Agilent board. His involvement and leadership in oncology research will provide Agilent with important insights and perspectives. As Agilent expands its focus in cancer diagnostics, we are ensuring we have the expertise on our board to be a successful, forward-thinking, thoughtful leader in this space.”
About Dr. Otis W. Brawley
Dr. Brawley is a Bloomberg Distinguished Professor with the Department of Oncology and Epidemiology at the Johns Hopkins University School of Medicine, and a leading authority on cancer screening and prevention, with a focus on closing racial, economic, and social inequalities in the prevention, detection, and treatment of cancer. In addition to his role at Johns Hopkins, he is a member of the National Cancer Institute Board of Scientific Advisors and the National Academy of Medicine.
Prior to assuming his current role at Johns Hopkins in 2019, Dr. Brawley served for 11 years as chief medical and scientific officer and EVP for Research at the American Cancer Society. In that position, he oversaw the largest private program funding cancer research in the U.S. In addition, Dr. Brawley has also served as director, Georgia Cancer Center, and chief of Hematology and Oncology at Grady Memorial Hospital in Atlanta. Dr. Brawley has also previously served in a medical and academic role at Emory University and a variety of roles with the National Cancer Institute.
Dr. Brawley was a Georgia Cancer Coalition Scholar and received the Key to St. Bernard Parish and the U.S. Public Health Service Meritorious Service Medal for his work as a PHS Commissioned Officer in the aftermath of Hurricane Katrina in 2005. He is also a recipient of the U.S. Dept. of Defense Distinguished Service Medal for his contributions to military medical education and received the Distinguished Service Award from the American Medical Association in 2019.
Dr. Brawley is currently a member of the board of directors at public biotech companies Incyte Corporation, Lyell Immunopharma, and PDS Biotechnology.
He received both his bachelor’s degree in chemistry and his medical degree from the University of Chicago.
About Agilent Technologies
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenue of $5.34 billion in the fiscal year 2020 and employs 16,400 people worldwide.
For more information: https://www.agilent.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.